Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Medicines that decrease blood pressure in the lungs may help idiopathic pulmonary fibrosis (IPF) patients function better. This study will test whether sildenafil improves the ability to exercise in patients with pulmonary fibrosis of unknown cause.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VA Office of Research and Development
• Treatments: Sildenafil Citrate

Criteria

Inclusion Criteria:

• Clinical diagnosis of IPF

• 40-85 years of age

• 6-minute walk distance 150-500 m

• FVC 40-90% predicted

• DLCO 30-90% predicted

Exclusion Criteria:

• Severe pulmonary hypertension

• Severe heart failure

• FEV1/FVC < 0.7